SUPPLEMENTARY APPENDIX 1

Clinical (Practice) Audit Report 2012

Your NameJansen SeheultDate Audit Commenced05/10/2012Date Audit Concluded09/10/2012TitlePoint of Care Testing as a tool for early recognition and management of
moderate and severe inpatient hyperglycaemia.

Background

Diabetes Mellitus (DM) is characterized by an elevated blood glucose level. This can be due to insulin resistance (type 2 diabetes mellitus), to type 1 diabetes, or occasionally to secondary causes. Type 2 diabetes accounts for 85-90% of diabetic cases. Worldwide \sim 200 million are known to have Diabetes. Type 2 DM affects about 5% of Irish adults.

Condition	Fasting	2 hour glucose	HbA _{1c}
	mmol/l(mg/dl)	mmol/l(mg/dl)	%
Normal	<6.1 (<110)	<7.8 (<140)	<6.0
Diabetes mellitus	≥7.0 (≥126)	≥11.1 (≥200)	≥6.5

This table shows diabetic diagnostic criteria reported by WHO/IDF:

Apart from the various micro-vascular and macro-vascular complications, there are three life-threatening emergencies in Diabetes Mellitus:

- Diabetic Ketoacidosis [Hyperglycaemia>11.1 mmol/L, pH<7.3, HCO3<15 mmol/L, ketonuria]
- Hyperosmolar Non-Ketotic hyperglycaemia [Hyperglycaemia>30 mmol/L, Serum osmolality>350mmol/kg, no acidosis, no ketonuria.
- Hypoglycaemia [cutoff points vary]

Hypoglycaemia tends to be adequately managed in hospitalized patients due to early autonomic and neuroglycopaenic signs and symptoms, except in patients on concurrent beta-blocker therapy. Hyperglycaemia is prevalent in the inpatient setting and is associated with increased morbidity and mortality in patients with and without diabetes. Too often hyperglycaemia is underrecognized, underreported, and suboptimally managed. Proactive assessment of inpatients' glycemic status and aggressive treatment approaches are needed. There is a recognized need for improved hyperglycaemia management in inpatients. While Diabetic Care Bundles are available, they are not widely followed and there are numerous problems in managing inpatient hyperglycaemia including:

- Limited access to guidelines or care pathways
- Non-physiologic sliding-scale insulin protocols that result in poor glycemic control or wide fluctuations in glucose levels
- Errors in glucose administration
- Failure to involve Diabetic team in a timely fashion due to lack of integration of services
- Reluctance to implement tight glycaemic control regimens in the inpatient setting due to higher tolerance on the part of medical staff.
- Reluctance to use intravenous or continuous subcutaneous insulin sliding scales.

The issue of glycaemic targets, appropriate education and access to resources, the need for noninvasive blood glucose monitoring, and the role of nursing staff are vital in addressing the above issue.

In this regard, a computerized Point of Care Glucometry System with daily audits of cases of hypo- and hyper-glycaemia, which is integrated with hospital teams, and the Diabetic Service may be a viable solution to targeting the issue of poor inpatient glucose control.

Aim(s) of the audit

The aim of the audit was to review the identification and management of patients with hypoglycaemia and with moderate and severe in-hospital hyperglycaemia.

- ➢ Hypoglycaemia [glucose <4.0]</p>
- ➤ Moderate hyperglycaemia [glucose 15-20 mmol/L]
- Severe hyperglycaemia [glucose >20 mmol/L]

Objectives

- 1. To identify all cases of moderate and severe hyperglycaemia
- 2. To identify all cases of hypoglycaemia
- 3. To determine whether patient location was related to incidence of hyperglycaemia
- 4. To determine whether patient location was related to incidence of hypoglycaemia
- To analyze the time to next glucose reading following the discovery of moderate or severe hyperglycaemia
- 6. To analyze the time to normalization of glucose following the discovery of moderate or severe hyperglycaemia.

Standards

Management of Hyperglycaemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline.

- 1. Bedside capillary POC testing as the preferred method for guiding ongoing
- 2. Glycemic management of individual patients.patients without a history of diabetes with BG greater than 7.8 mmol/liter (140 mg/dl) be monitored with bedside point of care (POC) testing for at least 24 to 48 h. Those with BG greater than 7.8 mmol/liter require ongoing POC testing with appropriate therapeutic intervention.
- For avoidance of hypoglycaemia, we suggest that antidiabetic therapy be reassessed when BG values fall below 5.6 mmol/liter (100 mg/dl). Modification of glucose-lowering treatment is usually necessary when BG

values are below 3.9 mmol/liter (70 mg/dl).

- POC testing can be discontinued in nondiabetic patients if all BG results are below 7.8 mmol/liter (140 mg/dl) without insulin therapy for a period of at least 24–48 h.
- 5. Hospitals provide administrative support for an interdisciplinary steering committee targeting a systems approach to improve care of inpatients with hyperglycaemia and diabetes.
- 6. Each institution establish a uniform method of collecting and evaluating POC testing data and insulin use information as a way of monitoring the safety and efficacy of the glycemic control program.

In May 2009, American Association of Clinical Endocrinologists (AACE) and the American Diabetes Association (ADA) revised their inpatient glycemic targets to 140–180 mg/dL [7.8 -10.0 mmol/L] in the ICU and non-ICU preprandial glucose levels below 140 mg/dL [7.8 mmol/L] and all random glucose levels below 180 mg/dL [10/0 mmol/L].

Methodology

1001 glucose results which had been measured by nurses on ward-based glucometers over a five day period between 05/10/2012 at 00:00 and 09/10/2012 at 12:00 were included in the audit. These were collected from the Cobas IT® Glucometry database (supplied by Roche Diagnostics Limited). In Tallaght Hospital, all ward-based glucometers are interfaced to this database for the purposes of the audit. Only patients with hyperglycaemia > 10.0 mmol/l [AACE/ADA recommendations] were used because the database does not record whether the patients were fasting or postprandial at the time of the glucose measurements.

The extracted glucose data was analyzed in Microsoft® Excel® Test results were omitted. Data were analyzed by individual glucose readings and then by patient, after omission of duplicate readings each day. Sub-analyses were done by ward location. Cases of moderate and severe hyperglycaemia were also charted temporaneously and summary statistics calculated.

Results

A total of 1001 glucose readings were retrieved from a 5-day period. There were 94 Test readings which were omitted, leaving 907 valid glucose recordings. There were approximately 200 glucometry samples taken each day. The majority of readings [60-87%] fell within the normoglycaemic range. Overall, 3.4% of readings were in the hypoglycaemia range. There were 258 recordings >10.0 mmol/L [i.e. the ADA cutoff for inpatient hyperglycaemia]. Approximately 10% of readings reflected either moderate or severe hyperglycaemia. Overall, only 2.4% of readings were in the severe hyperglycaemia category. The lowest glucose reading was 2.5 mmol/L and there were 10 readings <3.0 mmol/L. Two readings feel within the DKA criteria range [>30 mmol/L], with the highest glucose result being 33.2 mmol/L.

Glucose Level [mmol/L]	Total	09/10/2012	08/10/2012	07/10/2012	06/10/2012	05/10/2012
	31	0	5	7	6	13
<4.0	(3.4%)	(0.0%)	(2.1%)	(3.3%)	(3.2%)	(6.7%)
	618	66	171	140	125	116
4.0-10.0	(68.2%)	(86.8%)	(70.6%)	(66.4%)	(67.6%)	(60.1%)
	170	7	41	37	36	49
10.0-15.0	(18.7%)	(9.3%)	(16.9%)	(17.5%)	(19.5%)	(25.4%)
	66	3	19	20	13	11
15.0-20.0	(7.3%)	(3.9%)	(7.9%)	(9.5%)	(7.0%)	(5.7%)
	22	0	6	7	5	4
>20.0	(2.4%)	(0.0%)	(2.5%)	(3.3%)	(2.7%)	(2.1%)
	907	76	242	211	185	193

Table S1 showing glucose recordings stratified by glucose level and date of recording.



Figure S1 showing glucose recordings for the five day period.

Figures S2 and S3 show glucose recordings stratified by glucose level and by date. They show similar trends, i.e. the majority of readings were in the normoglycaemia range with more patients in the moderate hyperglycaemia range than in the severe hyperglycaemia range. The most recordings were taken on Monday 8th October [26.7%] and Sunday 7th October [23.2%]. The most cases of moderate and severe hyperglycaemia occurred on Sunday 7th October, 20 readings and 7 readings respectively.



Figure S2 showing glucose recordings stratified by glucose level and date.

Figure S3 showing glucose recordings stratified by date and glucose level.



Table S2 and Figure S4 show the number of individual patients who were either moderately or severely hyperglycaemic at any point in time during the course of a day. The highest reading was taken per patient each day. The most cases of moderate-severe hyperglycaemia occurred on Sunday and Monday.

Table S2 showing number of patients with moderate or severe hyperglycaemia per day.

Glucose Level	Tota	09/10/201	08/10/201	07/10/201	06/10/201	05/10/201
[mmol/L]	1	2	2	2	2	2
15.0-20.0	39	3	10	10	7	9
>20.0	13	0	4	3	3	3

Figure S4 showing number of patients with moderate or severe hyperglycaemia per day.



The majority of glucose readings in the moderate-severe range occurred on 4 wards [J, L, R and T]. R and T had the most cases of severe hyperglycaemia [see figure S5].



Figure S5 showing number of recordings within moderate or severe hyperglycaemia levels based on ward location.

When glucose readings were analyzed according to individual patients who had either moderate or severe hyperglycaemia, average time to subsequent glucose recording was up to 6 hours and average time to normalization or glucose was up to 10 hours. This is contrary to most targets in the standards of care for the management of inpatient hyperglycaemia. One case took up to 3 days for glucose levels to fall below 15 mmol/L. A few cases were well-managed with the minimum time to glucose normalization being 49 minutes.

Table S3 showing summary statistics for time to next glucometer reading and time to normalization of glucose levels for all patients with moderate or severe hyperglycaemia.

	Time to next glucometer	Time to glucose <15
	reading	mmol/L
Max (hh:mm:ss)	32:52:00	75:58:00
Min (hh:mm:ss)	0:02:00	0:49:00
Mean (hh:mm:ss)	5:50:19	9:53:15
Standard Deviation (hh:mm:ss)	5:54:47	12:58:52
Variance (hh:mm:ss)	1:27:25	7:01:17

Figures S6 through S10 highlight individual cases of hypo- and hyperglycaemia as they occurred over the 5 day audit window. They show the issues of widely fluctuating glucose values and the problem of hypoglycaemia when trying to achieve tight glycaemic control. They clearly indicate a need for better protocols and an integrated care pathway for the management of inpatients with hyperglycaemia.



Figure S6: Patient with moderate hyperglycaemia. Management of this patient was complicated by hypoglycaemia but adequate control was achieved within 36 hours.

Figure S7: Case showing two instances of hypoglycaemia which resolved [either spontaneously or with appropriate management] within 1-3 hours.





Figure S8: Inpatient with poor glycaemic control over the course of 5 days.

Figure S9: Case of severe hyperglycaemia and moderate hyperglycaemia in the same inpatient during a 5 day window.





Figure S10: Inpatient with wide fluctuations in glucose levels indicating poor management regimen.

Conclusions

A large proportion [30%] of glucose readings were above the AACE/ADA recommended cutoff target of 180mg/dl [10.0 mmol/L] for management of inpatient hyperglycaemia. 52 patients had at least moderate or severe hyperglycaemia. Three wards were idenitified with large numbers of hyperglycaemic recordings. When glucose readings in the moderate-severe hyperglycaemia range were identified, there were significant delays in subsequent glucose measurement and in achieving tight glycaemic control.

Recommendations and Action Plan

- 1. Daily reviews of glucose recordings by laboratory POCT manager or other nominated individual.
- Red flag system all glucose recordings within the moderate-severe hyperglycaemia range are notified to the relevant ward team, nursing staff, Diabetic Nurse Specialist. Recommendations will be made by Diabetic Nurse Specialist and POCT team regarding the need for alerting the hospital Diabetology Team.
- 3. Diabetes Care Bundles will be easily accessible on all wards by use of concise flow diagrams with adequate information about treatment of inpatient hypoand hyperglycaemia with treatment targets highlighted. This will aid standardization of patient care across all healthcare staff.

Recommended POCT Glucometry intervals will be provided based on patients' clinical history, reason for admission, clinical status and prior glucose values. Reaudit at 6-monthly intervals to evaluate effectivess of the above strategies. This should address the limitations of this audit, including lack of access to patient history. Re-audit should be done in close liaison with Diabetology Team and Diabetic Nurse Specialists.

References

- Inzucchi SE. Clinical practice. Diagnosis of diabetes. N Engl J Med. 2012 Aug 9;367(6):542-50. Review.
- Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of Hyperglycaemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, January 2012, 97 (1):16–38.
- Abourizk NN, Vora CK, Verma PK. Inpatient diabetology. The new frontier. J Gen Intern Med. 2004 May;19(5 Pt 1):466-71.
- 4. Juneja R. Hyperglycaemia management in the hospital: about glucose targets and process improvements. Postgrad Med. 2008 Nov;120(4):38-50.
- Schmeltz LR, Ferrise C. Glycemic management in the inpatient setting. Hosp Pract (Minneap). 2012 Apr;40(2):44-55.
- Schmeltz LR, Ferrise C. Glycemic management in the inpatient setting. Hosp Pract (Minneap). 2012 Apr;40(2):44-55.

SUPPLEMENTARY APPENDIX 2

1. User Interface

A ribbon interface was created for user interaction. This interface is shown in Figure S1 of Supplementary Appendix 2. The Excel® data file was loaded using this interface and processed according to a start date and end date entered in the dropdown menus. The ribbon interface had buttons for generation of reports and charts outlined in the sections below.

2. Data File Creation

Daily downloads of glucometry results were done from the Cobas IT® 1000 database and saved in .xls format. Daily data files were appended to a larger Excel® Database containing results from January 1st, 2014. A sample showing the data file and headings is shown in Figure S2 of Supplementary Appendix 2.

3. Data classification by date and glucose level

Data were first filtered according to the date range entered in the ribbon interface. During the filtering process, all values stored on the database as "> 33.3" were assigned a value of 33.3 mmol/L and all values stored as "< .6" were converted to a value of 0.6 mmol/L to allow data categorization.

Data were then classified according to the following POCT-BG values:

- < 4 mmol/L : Hypoglycaemia
- 4 10 mmol/L : Normoglycaemia
- 10 15 mmol/L : Mild hyperglycaemia
- 15 20 mmol/L : Moderate hyperglycaemia
- > 20 mmol/L : Severe hyperglycaemia

These cutoffs were chosen from local standards for in hospital glycaemia control based on previous annual audits.

4. Generation of reports for dysglycaemic results

Reports were generated for POCT-BG results in the form of a pivot table, as shown in Figure S3 of the Supplementary Appendix. Results filters included date, ward location and glucose category or level. Results could also be collapsed by patient ID and ward location, giving summary statistics of mean, maximum, minimum and number of results by patient ID or ward location. Reports were also generated in the format shown in Figure S4 of Supplementary Appendix 2, which allowed each dysglycaemic result to be uploaded to the Laboratory Information System.

5. Generation of Charts

The ribbon interface allowed selection of three different graphical displays: 1) Bar charts showing the percentage of POCT-BG values within each category over date; 2) Bar charts showing the number and percentage of results within each glucose category over ward location; and 3) Line graphs showing all POCT-BG levels for individual patients within the date range analysed. See Figures S5-S8 of Supplementary Appendix 2 for sample graphs.

6. Alert system on tablet devices

Toshiba Encore® 8.0 inch touchscreen tablets [Toshiba Corporation, Tokyo, Japan] with the Windows® 8.1 [Microsoft, WA, USA] operating system and Microsoft® Office Home and Student 2013 [Microsoft, WA, USA] were used in this study. All devices were password protected and data was stored on an encrypted drive (J: directory) on the device. Daily uploads of the glucometry data file to the J: folder were done.

Figure S1: Ribbon User Interface for Excel® Macros

A1	Home			>	FILE
•	Imj	Data Form	💝 Dropb	Excel F	HOME
	port Dat.	at	ox Folde	ile	IN
×	a File		4		SERT
f_{x}		4	End Dat	Start Da	PAGE LAYO
	Date Range		ie select date →	ite select date 🔹	UT FORMULAS
		Output	Generate	111	DATA
		Report Re	ntersative D		REVIEW
	Reports	port		Report	VIEW
			Dates	Date select date	DEVELOPER
		Ta			Lab Audit
		ibles Charts			
	Charts	Individual Patient	Patients By Location	Patients By Date	
<	>				Sign in 🔎

¢	125% (=)													Ready 🔛
•				=				4						IA A P PI Result Quer
•		31/03/2014 06:09	~system~	UU13049623	WSU 11013	471698	1204378	P		<u>6</u>	Glu2	Tallaght - AC	150358 B	43 31/03/2014 05:52
		31/03/2014 09:24	~system~	UU13049623	WSU 11013	471698	1155938	PFAN,PU		7.8	Glu2	Tallaght - AC	150358 B	42 31/03/2014 09:19
		31/03/2014 11:59	~system~	UU12514428	WSU 20.06.13	471698	1142968	PFAN,PU	_	7.5	Glu2	Tallaght - AC	150358 B	41 31/03/2014 11:20
		31/03/2014 13:23	~system~	UU13049623	WSU 11013	471698	1155938	PFAN,PU	-	9.9	Glu2	Tallaght - AC	150358 B	40 31/03/2014 13:21
		31/03/2014 15:20	~system~	UU13049623	WSU 11013	471698	1155938	PFAN,PU		9.1	Glu2	Tallaght - AC	150358 B	39 31/03/2014 15:10
		31/03/2014 17:54	~system~	UU13049623	WSU 11013	471698	1155938	PFAN,PU		13.1	Glu2	Tallaght - AC	150358 B	38 31/03/2014 17:41
		31/03/2014 19:55	~system~	UU13049623	WSU 11013	471698	1155938	PFAN,PU		10.9	Glu2	Tallaght - AC	150358 B	37 31/03/2014 19:37
		31/03/2014 22:06	~system~	UU13049623	WSU 11013	471698	1187090	PFAN,PU		9.8	Glu2	Tallaght - AC	150358 B	36 31/03/2014 21:56
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1209612	PA	-	5 ⁸	Glu2	Tallaght - AC	40353088 N/A	35 17/03/2014 12:16
		10/03/2014 14:14	0708313	UU13049623	WSU 11013	471264	1210521	PFAC, PA	_	12	Glu2	Tallaght - AC	6052613 N/A	34 06/03/2014 12:03
		03/03/2014 14:21	0708313	UU13049623	WSU 11013	471264	0697354	PFAN,PA		12.5	Glu2	Tallaght - AC	3486778 N/A	33 02/03/2014 11:56
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1165194	PFAN,PA		7.6	Glu2	Tallaght - AC	2358498 N/A	32 15/03/2014 06:58
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1165194	PFAC,PA	-	16.7	Glu2	Tallaght - AC	2358498 N/A	31 15/03/2014 07:00
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1165194	PFAN,PA		10.7	Glu2	Tallaght - AC	2358498 N/A	30 15/03/2014 20:44
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1186507	PFAC,PA	_	17.8	Glu2	Tallaght - AC	2358498 N/A	29 16/03/2014 06:32
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1165194	PFAN,PA	_	11.8	Glu2	Tallaght - AC	2358498 N/A	28 16/03/2014 07:02
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1165194	PFAN,PA	<u> </u>	7.8	Glu2	Tallaght - AC	2358498 N/A	27 16/03/2014 07:04
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1165194	PFAN,PA	_	12.3	Glu2	Tallaght - AC	2358498 N/A	26 17/03/2014 07:03
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1165194	PFAN,PA		12.7	Glu2	Tallaght - AC	2358498 N/A	25 17/03/2014 07:04
		24/03/2014 16:25	0708313	UU12514428	WSU 20.06.13	471698	1186507	PFAN,PA		7.3	Glu2	Tallaght - AC	2358498 N/A	24 23/03/2014 06:45
		28/03/2014 11:50	0708313	UU13049623	WSU 11013	471698	1165194	PFAN,PA	-	11.2	Glu2	Tallaght - AC	2358498 N/A	23 27/03/2014 19:33
		28/03/2014 11:50	0708313	UU13049623	WSU 11013	471698	1165194	PFAM,PA	-	> 33.3	Glu2	Tallaght - AC	2358498 N/A	22 28/03/2014 11:34
		02/04/2014 14:48	0708313	UU13049623	WSU 11013	471698	1165194	PFAN,PA	-	Ŧ	Glu2	Tallaght - AC	2358498 N/A	21 28/03/2014 12:29
		02/04/2014 14:48	0708313	UU13049623	WSU 11013	471698	1165194	PFAC,PA	-	24.9	Glu2	Tallaght - AC	2358498 N/A	20 28/03/2014 16:09
		02/04/2014 14:48	0708313	UU13049623	WSU 11013	471698	1165194	PFAN,PA	<u> </u>	15.4	Glu2	Tallaght - AC	2358498 N/A	19 28/03/2014 16:36
		02/04/2014 14:48	0708313	UU13049623	WSU 11013	471698	1165194	PFAN,PA	-	13.1	Glu2	Tallaght - AC	2358498 N/A	18 28/03/2014 16:38
		02/04/2014 14:48	0708313	UU12514428	WSU 20.06.13	471698	1142968	PFAN,PA	_	9.1	Glu2	Tallaght - AC	2358498 N/A	17 28/03/2014 19:01
		03/03/2014 14:21	0708313	UU13049623	WSU 11013	471264	1165194	PFAC,PA	_	20.2	Glu2	Tallaght - AC	2356328 N/A	16 01/03/2014 19:27
		06/03/2014 10:31	0708313	UU12514428	WSU 20.06.13	471264	1185438	PFAN,PA		7	Glu2	Tallaght - AC	2356328 N/A	15 03/03/2014 12:09
		10/03/2014 14:13	0708313	UU12514428	WSU 20.06.13	471264	1248324	PFAN,PA		6.5	Glu2	Tallaght - AC	2356328 N/A	14 06/03/2014 18:18
		10/03/2014 14:12	0708313	UU13049623	WSU 11013	471264	1186507	PA	-	5.1	Glu2	Tallaght - AC	2356328 N/A	13 10/03/2014 00:43
		13/03/2014 10:05	0708313	UU12514428	WSU 20.06.13	471264	1209612	PFAN,PA		9.5	Glu2	Tallaght - AC	2356328 N/A	12 11/03/2014 12:23
		13/03/2014 10:05	0708313	UU12514428	WSU 20.06.13	471264	1209612	PFAC,PA		22.5	Glu2	Tallaght - AC	2356328 N/A	11 12/03/2014 13:24
		13/03/2014 10:05	0708313	UU12514428	WSU 20.06.13	471264	1165194	PFAN,PA		12.4	Glu2	Tallaght - AC	2356328 N/A	10 12/03/2014 21:17
		13/03/2014 10:05	0708313	UU12514428	WSU 20.06.13	471264	1165194	PA		5.5	Glu2	Tallaght - AC	2356328 N/A	9 13/03/2014 06:50
		13/03/2014 10:05	0708313	UU12514428	WSU 20.06.13	471264	1165194	PFAN,PA		6.9	Glu2	Tallaght - AC	2356328 N/A	8 13/03/2014 06:54
		13/03/2014 10:05	0708313	UU12514428	WSU 20.06.13	471264	1165194	PFAN,PA		10.8	Glu2	Tallaght - AC	2356328 N/A	7 13/03/2014 06:56
		13/03/2014 10:05	0708313	UU12514428	WSU 20.06.13	471264	1165127	PA	- *	9	Glu2	Tallaoht - AC	2356328 N/A	6 13/03/2014 07:15
		14/03/2014 14:48	0708313	UU12514428	WSU 20.06 13	471264	1165194	PFAC PA	- "-	17.5	Gluž	Tallaght - AC	2356328 N/A	5 14/03/2014 07:04
		14/03/2014 14:48	0708313	11112514428	WSU 20 06 13	471264	1165194	PEAN PA	- ²	12.6	Gluy	Tallanht - AC	V/N 8653566	4 14/03/2014 07-14
<u> </u>		28/03/2014 11:50	0708313	11113049623	WSU 11013	471698	1200041	DEAN DA	- ¹	13.8	Gluy	Tallanht - AC	448933 N/A	3 25/03/2014 14-21
	The sector	28/03/2014 11:50	0708313	UU13049623	WSU 11013	471698	1209841	PFAN PA	4	14.7	Glu2	Tallanht - AC	448933 N/A	2 25/03/2014 16·58
	Host Cant Date	Deviewed Date	Deviewed h	Corial Number	Instrument Name	TeetIOT	lleor .	Alarme	Validation	Doenil+	in Teet	Instrument Loca	Dationt ID Last Name	1 Date & Time
	o	z	M	_	ĸ	<u> </u>	_	I	a	n	Π		B	Δ
<														8
		Editing	Cells			Styles				Number 5	e	Alignmer	Font 12	Clipboard
	, p	Clear	rt Delete Format	⇒ Inser	Linked Cell Note	Input	Explanatory	mat Check Cell	Conditional For Formatting * as To	°°** °°°** • °% ~ \$	🔤 Merge & Center 🔹	111 101 111 111 111	в / Ц ∽ 🔄 ∽ 📥 ∽	Paste Sormat Painter
		Σ AutoSum *	.	tion	Neutral Calcula	Good	Bad	Normal		ieneral ×	Wrap Text	** **	Arial × 8 × A A	Cut
	Ð									at	Developer Acrob	ata Review View	ert Page Layout Formulas [File Home In:
×	0	a design of the second se					Microsoft Excel	nonymized Data File -	P		-			▲ 1 → 1 → 1 = 1
3														

Figure S2: Anonymised sample data file extracted from Cobas IT®

	- 100 - U	The line of the li	■ Tallaght - OK	Tallaght - MG	■Tallaght - L		■ Tallaght - E	Tallaght - CU	Tallaght - C	Tallaght - AD	Tallaght - AC	Tallaght - S		■ Tallaght - PD	Tallapht - P	Tallacht M																	Tallaght - LN	® Tallapht - I	Instrument Location	Date Level	A1 •	me Import Data File	me Format
																	Z	E N		W	⊞R			Ð							⊟C ⊟361954	۳D	ж		Last Name Patient ID	(AII) (AII)	fx.	Date Range	 End Date select date
All Determine The model of the part of																								±6.5 3/25/2014	=6.3 3/23/2014	B5.4 3/26/2014	■4.7 3/24/2014	3/29/2014		E4 3/30/2014	3 3.1 3/31/2014				Result Date & Tim			Rep	Generate Interactive Daily Output Report Report
Total of the biology of the		0.5	6.9	7.9	8.3	7.9	7.3	8.5	6.6	9.6	11.2	7.1	11.0	5.8	8.4	13.0	9.0	7.1	9.3	12.6	11.6	7.3	7.7	6:19 6.5	6:14 6.3	6:06 5.4	5:16 4.7	6:13 4.5	4.3	6:14 4.0	6:12 3.1	5.4	16.4	9.3	e Vaverage of Result Mi			orts	All Dates
Patients By Location Repert. Curr. Patient By Location Patient By Location 20.0		K C	3.4	2.7	4.1	4.4	3.4	4.4	3.2	2.5	3.2	4	2.9	1.3	3.1	э.,	5.2	7	7	7	4.8	5.9	2.5	10 A	6.3	5.4	4.7	45 ť	4.3	4	3.1	3.4	3.8	3.4	n of Result M				Update Update Tables Charts
Non Regent. Currer 24 26 26 27 1 1 1 1 1 1 1 1 1 1 1 1 1		V UC	23.1	17.3	15.3	19.9	18.7	17.5	11.9	33	33	17.7	21.3	24	26	4 C L	22.6	7.2	11.8	16.1	17.7	9.8	20.2	06.5	6.3	5.4	4.7	45 f	4.3	4	3.1	9	27.3	24.5	ax of Result Cou			Charts	 Patients By Loca Individual Patier
		200	8	129	26	158	118	71	36	194	218	162	56	247	118	0/	1 6	2	10	25	10	7	100	т ^с	. ₁₄	1	1	н н		H	1	16	96	200	nt of Level			PDF Exp	tion Reports C
																																						ort Help	harts

and "Last Name/ Patient ID".

Figure S3: Anonymised interactive report generated by Macros. Adjustable data fields include "Date", "Glucose Level", "Instrument Location"



Figure S4: Anonymised sample report by day for uploading to the LIS.



Figure S5: Vertical bar graph showing the percentage of results in each glucose level or category by date. Adjustable fields include "Instrument

Location", "Glucose Level" and "Date"



Figure S6: Vertical bar graph showing the number of results in each glucose level or category by date. Adjustable fields include "Instrument

Location", "Glucose Level" and "Date"



Figure S7: Stacked vertical bar graph showing the number of results in each glucose level by Ward location. Adjustable fields include

"Instrument Location", "Glucose Level" and "Date".



Figure S8: Line graph showing all POCT-BG results for a single patient over a specified date range. Results are listed in tabular form on the left of the graph. Patients can be selected by typing the patient ID into the yellow box or from the scrollable list (anonymised) on the right.